SCOTTSDALE, Ariz., March 6 /PRNewswire-FirstCall/ -- Research and development biotechnology company ImmuneRegen BioSciences, Inc. a wholly owned subsidiary of IR BioSciences Holdings, Inc. , announced today the appointment of Kelly McQueen, MD, MPH to it's Drug Development Advisory Board. Dr. McQueen's consultation will be utilized in the development of ImmunneRegen's Homspera(TM).
Kelly McQueen, MD, MPH is a practicing anesthesiologist and public health consultant in Phoenix, AZ. She serves as faculty at the Harvard Humanitarian Initiative, and consults for State and National, and International organizations on Infectious Disease, Disaster Planning and Civilian Military Coordination for Humanitarian Aid. Dr. McQueen teaches infectious disease threat management and treatment for the International Committee for the Red Cross (ICRC) course on Health Emergencies in Large Populations (HELP). She has a long-term commitment to disaster management and humanitarian aid and she works for several organizations overseas every a year.
Dr. McQueen received her bachelor's degree from Colorado College, her medical degree from the University of Vermont College of Medicine and her Masters in Public Health from the Harvard School of Public Health. She published numerous articles in peer review journals, authored and co-authored chapters on anesthetic and public health topics, and has presented her work at national and international conferences. Dr. McQueen published two children's books, an elementary school curriculum for HIV/AIDS education and a children's instructional video on HIV/AIDS.
About ImmuneRegen BioSciences, Inc.
IR BioSciences Holdings Inc., through its wholly owned subsidiary ImmuneRegen BioSciences, Inc., is a development stage biotechnology company focused on the research and development of Homspera(TM) and its derivatives Radilex(TM) and Viprovex(TM), which are designed to be used as countermeasures for multiple homeland security bioterrorism threats. Homspera is derived from modified homeostatic Substance P, a naturally occurring peptide immunomodulator and homeostatic compound with the dual effect of improving pulmonary function and the stimulation of the human immune system. For more information, please visit the company's website at www.immuneregen.com.
Certain statements about the Company's future expectations, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. The Company's actual results could differ materially from expected results as a result of a number of factors, including, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and others set forth in the Company's periodic report on Form 10-Q for the three months ended September 30, 2005 as filed with the Securities and Exchange Commission.
Contact: W. Jason Grimley Spelling Communications 310-477-9500 jgrimley@spellcom.com
ImmuneRegen BioSciences, Inc.CONTACT: W. Jason Grimley of Spelling Communications, +1-310-477-9500,jgrimley@spellcom.com, for ImmuneRegen BioSciences, Inc.
Web site: http://www.immuneregen.com/
